IL-17A/F Inhibitor (CSPC-2232)
Psoriasis
Key Facts
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.
View full company profileAbout CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.
View full company profileTherapeutic Areas
Other Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| CYPS317 | FibroBiologics | Discovery |
| PEP Biologic™ | Intent Biologics | Unknown |
| DMT410 | Dermata Therapeutics | Preclinical |
| IL23R program | Acellera | Pre-clinical |
| Undisclosed Psoriasis Program | Nepsone | Preclinical |
| TEM-1657 (Topical) | Temisis | Pre-clinical |
| TEM-1657 (Oral) | Temisis | Pre-clinical |
| AIM Platform | Phaim Pharma | Pre-clinical |
| orismilast | UNION therapeutics | Phase 2 |
| CT-P55 | Celltrion | Phase 3 |
| JNJ-77242113 | Johnson & Johnson | Phase 3 |
| Zasocitinib (TAK-279) | Takeda Pharmaceutical | Phase 3 |